nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—CYP2C9—cardial valve—systemic scleroderma	0.0338	0.581	CbGeAlD
Bosentan—CYP2C9—Leflunomide—systemic scleroderma	0.0316	0.608	CbGbCtD
Bosentan—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0113	0.218	CbGbCtD
Bosentan—CYP3A4—Prednisone—systemic scleroderma	0.00906	0.174	CbGbCtD
Bosentan—EDNRB—tendon—systemic scleroderma	0.00509	0.0875	CbGeAlD
Bosentan—EDNRB—lung—systemic scleroderma	0.00446	0.0768	CbGeAlD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—EDN1—systemic scleroderma	0.00436	0.139	CbGpPWpGaD
Bosentan—ABCB11—digestive system—systemic scleroderma	0.00431	0.0743	CbGeAlD
Bosentan—EDNRA—tendon—systemic scleroderma	0.0042	0.0724	CbGeAlD
Bosentan—EDNRA—lung—systemic scleroderma	0.00369	0.0635	CbGeAlD
Bosentan—EDNRB—Endothelins—COL1A2—systemic scleroderma	0.00237	0.0754	CbGpPWpGaD
Bosentan—EDNRB—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00232	0.0739	CbGpPWpGaD
Bosentan—EDNRB—Endothelin Pathways—EDN1—systemic scleroderma	0.00215	0.0684	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—COL1A2—systemic scleroderma	0.0017	0.0539	CbGpPWpGaD
Bosentan—EDNRA—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00166	0.0529	CbGpPWpGaD
Bosentan—EDNRA—Endothelin Pathways—EDN1—systemic scleroderma	0.00154	0.049	CbGpPWpGaD
Bosentan—CYP2C9—digestive system—systemic scleroderma	0.00146	0.0252	CbGeAlD
Bosentan—EDNRB—Endothelin Pathways—NOS3—systemic scleroderma	0.00131	0.0417	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—EDN1—systemic scleroderma	0.00128	0.0408	CbGpPWpGaD
Bosentan—CYP3A4—digestive system—systemic scleroderma	0.00111	0.0192	CbGeAlD
Bosentan—EDNRB—Endothelins—MMP1—systemic scleroderma	0.00108	0.0343	CbGpPWpGaD
Bosentan—EDNRA—Endothelin Pathways—NOS3—systemic scleroderma	0.000939	0.0298	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—EDN1—systemic scleroderma	0.000918	0.0292	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—MMP1—systemic scleroderma	0.000772	0.0245	CbGpPWpGaD
Bosentan—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000574	0.000668	CcSEcCtD
Bosentan—Irritability—Methotrexate—systemic scleroderma	0.000574	0.000668	CcSEcCtD
Bosentan—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000573	0.000667	CcSEcCtD
Bosentan—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000572	0.000666	CcSEcCtD
Bosentan—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00057	0.000664	CcSEcCtD
Bosentan—Fatigue—Mycophenolic acid—systemic scleroderma	0.00057	0.000663	CcSEcCtD
Bosentan—Mood swings—Methotrexate—systemic scleroderma	0.000569	0.000663	CcSEcCtD
Bosentan—Nausea—Mometasone—systemic scleroderma	0.000568	0.000662	CcSEcCtD
Bosentan—Anorexia—Lisinopril—systemic scleroderma	0.000567	0.000661	CcSEcCtD
Bosentan—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000566	0.00066	CcSEcCtD
Bosentan—Weight increased—Prednisone—systemic scleroderma	0.000566	0.000659	CcSEcCtD
Bosentan—Constipation—Mycophenolic acid—systemic scleroderma	0.000565	0.000658	CcSEcCtD
Bosentan—Pain—Mycophenolic acid—systemic scleroderma	0.000565	0.000658	CcSEcCtD
Bosentan—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000565	0.000658	CcSEcCtD
Bosentan—Weight decreased—Prednisone—systemic scleroderma	0.000562	0.000655	CcSEcCtD
Bosentan—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000561	0.000654	CcSEcCtD
Bosentan—Hyperglycaemia—Prednisone—systemic scleroderma	0.000561	0.000653	CcSEcCtD
Bosentan—Cough—Mycophenolate mofetil—systemic scleroderma	0.000557	0.000649	CcSEcCtD
Bosentan—Hypotension—Lisinopril—systemic scleroderma	0.000556	0.000648	CcSEcCtD
Bosentan—Dizziness—Captopril—systemic scleroderma	0.000556	0.000647	CcSEcCtD
Bosentan—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000555	0.000646	CcSEcCtD
Bosentan—Urticaria—Leflunomide—systemic scleroderma	0.00055	0.000641	CcSEcCtD
Bosentan—Body temperature increased—Leflunomide—systemic scleroderma	0.000547	0.000638	CcSEcCtD
Bosentan—Abdominal pain—Leflunomide—systemic scleroderma	0.000547	0.000638	CcSEcCtD
Bosentan—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000546	0.000636	CcSEcCtD
Bosentan—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000544	0.000633	CcSEcCtD
Bosentan—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000544	0.000633	CcSEcCtD
Bosentan—Myocardial infarction—Prednisone—systemic scleroderma	0.000543	0.000633	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000542	0.000631	CcSEcCtD
Bosentan—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000542	0.000631	CcSEcCtD
Bosentan—Hypersensitivity—Azathioprine—systemic scleroderma	0.00054	0.000629	CcSEcCtD
Bosentan—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00054	0.000629	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00054	0.000629	CcSEcCtD
Bosentan—Insomnia—Lisinopril—systemic scleroderma	0.000538	0.000627	CcSEcCtD
Bosentan—EDNRB—G alpha (q) signalling events—EDN1—systemic scleroderma	0.000537	0.0171	CbGpPWpGaD
Bosentan—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000537	0.000626	CcSEcCtD
Bosentan—Paraesthesia—Lisinopril—systemic scleroderma	0.000534	0.000622	CcSEcCtD
Bosentan—Vomiting—Captopril—systemic scleroderma	0.000534	0.000622	CcSEcCtD
Bosentan—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000532	0.00062	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000531	0.0169	CbGpPWpGaD
Bosentan—Dyspnoea—Lisinopril—systemic scleroderma	0.00053	0.000618	CcSEcCtD
Bosentan—Rash—Captopril—systemic scleroderma	0.00053	0.000617	CcSEcCtD
Bosentan—Dermatitis—Captopril—systemic scleroderma	0.000529	0.000616	CcSEcCtD
Bosentan—Somnolence—Lisinopril—systemic scleroderma	0.000529	0.000616	CcSEcCtD
Bosentan—Headache—Captopril—systemic scleroderma	0.000526	0.000613	CcSEcCtD
Bosentan—Dyspepsia—Lisinopril—systemic scleroderma	0.000524	0.00061	CcSEcCtD
Bosentan—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000522	0.000608	CcSEcCtD
Bosentan—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000522	0.000608	CcSEcCtD
Bosentan—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000521	0.000607	CcSEcCtD
Bosentan—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000521	0.000607	CcSEcCtD
Bosentan—Asthma—Methotrexate—systemic scleroderma	0.000519	0.000605	CcSEcCtD
Bosentan—Infection—Mycophenolate mofetil—systemic scleroderma	0.000518	0.000603	CcSEcCtD
Bosentan—Decreased appetite—Lisinopril—systemic scleroderma	0.000517	0.000602	CcSEcCtD
Bosentan—Eosinophilia—Methotrexate—systemic scleroderma	0.000514	0.000599	CcSEcCtD
Bosentan—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000514	0.000598	CcSEcCtD
Bosentan—Fatigue—Lisinopril—systemic scleroderma	0.000513	0.000598	CcSEcCtD
Bosentan—Shock—Mycophenolate mofetil—systemic scleroderma	0.000513	0.000597	CcSEcCtD
Bosentan—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000511	0.000596	CcSEcCtD
Bosentan—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00051	0.000595	CcSEcCtD
Bosentan—Hypersensitivity—Leflunomide—systemic scleroderma	0.00051	0.000594	CcSEcCtD
Bosentan—Constipation—Lisinopril—systemic scleroderma	0.000509	0.000593	CcSEcCtD
Bosentan—Pain—Lisinopril—systemic scleroderma	0.000509	0.000593	CcSEcCtD
Bosentan—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000509	0.000593	CcSEcCtD
Bosentan—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000506	0.00059	CcSEcCtD
Bosentan—Bradycardia—Prednisone—systemic scleroderma	0.000506	0.00059	CcSEcCtD
Bosentan—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000504	0.000587	CcSEcCtD
Bosentan—Diarrhoea—Azathioprine—systemic scleroderma	0.000502	0.000584	CcSEcCtD
Bosentan—Haemoglobin—Prednisone—systemic scleroderma	0.0005	0.000582	CcSEcCtD
Bosentan—Nausea—Captopril—systemic scleroderma	0.000499	0.000581	CcSEcCtD
Bosentan—Haemorrhage—Prednisone—systemic scleroderma	0.000497	0.000579	CcSEcCtD
Bosentan—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000497	0.000579	CcSEcCtD
Bosentan—Asthenia—Leflunomide—systemic scleroderma	0.000497	0.000579	CcSEcCtD
Bosentan—Pruritus—Leflunomide—systemic scleroderma	0.00049	0.000571	CcSEcCtD
Bosentan—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000487	0.000567	CcSEcCtD
Bosentan—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000487	0.000567	CcSEcCtD
Bosentan—Dysuria—Methotrexate—systemic scleroderma	0.000486	0.000566	CcSEcCtD
Bosentan—Neutropenia—Methotrexate—systemic scleroderma	0.000486	0.000566	CcSEcCtD
Bosentan—Dizziness—Azathioprine—systemic scleroderma	0.000485	0.000565	CcSEcCtD
Bosentan—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000483	0.000562	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000481	0.0153	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000475	0.000553	CcSEcCtD
Bosentan—Asthenia—Mycophenolic acid—systemic scleroderma	0.000474	0.000552	CcSEcCtD
Bosentan—Diarrhoea—Leflunomide—systemic scleroderma	0.000474	0.000552	CcSEcCtD
Bosentan—Urticaria—Lisinopril—systemic scleroderma	0.000473	0.000551	CcSEcCtD
Bosentan—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000472	0.000549	CcSEcCtD
Bosentan—Abdominal pain—Lisinopril—systemic scleroderma	0.00047	0.000548	CcSEcCtD
Bosentan—Body temperature increased—Lisinopril—systemic scleroderma	0.00047	0.000548	CcSEcCtD
Bosentan—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000468	0.000545	CcSEcCtD
Bosentan—Pruritus—Mycophenolic acid—systemic scleroderma	0.000467	0.000544	CcSEcCtD
Bosentan—Vomiting—Azathioprine—systemic scleroderma	0.000466	0.000543	CcSEcCtD
Bosentan—Pneumonia—Methotrexate—systemic scleroderma	0.000466	0.000543	CcSEcCtD
Bosentan—Eye disorder—Prednisone—systemic scleroderma	0.000465	0.000541	CcSEcCtD
Bosentan—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000465	0.000541	CcSEcCtD
Bosentan—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000463	0.00054	CcSEcCtD
Bosentan—Infestation—Methotrexate—systemic scleroderma	0.000463	0.000539	CcSEcCtD
Bosentan—Infestation NOS—Methotrexate—systemic scleroderma	0.000463	0.000539	CcSEcCtD
Bosentan—Rash—Azathioprine—systemic scleroderma	0.000462	0.000539	CcSEcCtD
Bosentan—Dermatitis—Azathioprine—systemic scleroderma	0.000462	0.000538	CcSEcCtD
Bosentan—Flushing—Prednisone—systemic scleroderma	0.000462	0.000538	CcSEcCtD
Bosentan—Headache—Azathioprine—systemic scleroderma	0.000459	0.000535	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000459	0.000535	CcSEcCtD
Bosentan—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000459	0.000535	CcSEcCtD
Bosentan—Dizziness—Leflunomide—systemic scleroderma	0.000458	0.000533	CcSEcCtD
Bosentan—Renal failure—Methotrexate—systemic scleroderma	0.000455	0.00053	CcSEcCtD
Bosentan—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000453	0.000528	CcSEcCtD
Bosentan—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000452	0.000526	CcSEcCtD
Bosentan—Stomatitis—Methotrexate—systemic scleroderma	0.000451	0.000526	CcSEcCtD
Bosentan—Angiopathy—Prednisone—systemic scleroderma	0.000451	0.000526	CcSEcCtD
Bosentan—Conjunctivitis—Methotrexate—systemic scleroderma	0.00045	0.000524	CcSEcCtD
Bosentan—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00045	0.000524	CcSEcCtD
Bosentan—Immune system disorder—Prednisone—systemic scleroderma	0.000449	0.000523	CcSEcCtD
Bosentan—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000446	0.000519	CcSEcCtD
Bosentan—Pain—Mycophenolate mofetil—systemic scleroderma	0.000446	0.000519	CcSEcCtD
Bosentan—Haematuria—Methotrexate—systemic scleroderma	0.000442	0.000514	CcSEcCtD
Bosentan—Vomiting—Leflunomide—systemic scleroderma	0.00044	0.000513	CcSEcCtD
Bosentan—Hypersensitivity—Lisinopril—systemic scleroderma	0.000438	0.000511	CcSEcCtD
Bosentan—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000438	0.00051	CcSEcCtD
Bosentan—Dizziness—Mycophenolic acid—systemic scleroderma	0.000437	0.000509	CcSEcCtD
Bosentan—Epistaxis—Methotrexate—systemic scleroderma	0.000437	0.000509	CcSEcCtD
Bosentan—Rash—Leflunomide—systemic scleroderma	0.000437	0.000509	CcSEcCtD
Bosentan—Dermatitis—Leflunomide—systemic scleroderma	0.000436	0.000508	CcSEcCtD
Bosentan—Mental disorder—Prednisone—systemic scleroderma	0.000436	0.000508	CcSEcCtD
Bosentan—Nausea—Azathioprine—systemic scleroderma	0.000436	0.000507	CcSEcCtD
Bosentan—Headache—Leflunomide—systemic scleroderma	0.000434	0.000505	CcSEcCtD
Bosentan—Malnutrition—Prednisone—systemic scleroderma	0.000433	0.000504	CcSEcCtD
Bosentan—Erythema—Prednisone—systemic scleroderma	0.000433	0.000504	CcSEcCtD
Bosentan—Asthenia—Lisinopril—systemic scleroderma	0.000427	0.000497	CcSEcCtD
Bosentan—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000426	0.000497	CcSEcCtD
Bosentan—Pruritus—Lisinopril—systemic scleroderma	0.000421	0.00049	CcSEcCtD
Bosentan—Vomiting—Mycophenolic acid—systemic scleroderma	0.00042	0.000489	CcSEcCtD
Bosentan—Haemoglobin—Methotrexate—systemic scleroderma	0.000418	0.000487	CcSEcCtD
Bosentan—Rash—Mycophenolic acid—systemic scleroderma	0.000417	0.000485	CcSEcCtD
Bosentan—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000416	0.000485	CcSEcCtD
Bosentan—Hepatitis—Methotrexate—systemic scleroderma	0.000416	0.000484	CcSEcCtD
Bosentan—Haemorrhage—Methotrexate—systemic scleroderma	0.000416	0.000484	CcSEcCtD
Bosentan—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000414	0.000482	CcSEcCtD
Bosentan—Headache—Mycophenolic acid—systemic scleroderma	0.000414	0.000482	CcSEcCtD
Bosentan—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000412	0.00048	CcSEcCtD
Bosentan—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000412	0.00048	CcSEcCtD
Bosentan—Nausea—Leflunomide—systemic scleroderma	0.000411	0.000479	CcSEcCtD
Bosentan—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000411	0.000478	CcSEcCtD
Bosentan—Vision blurred—Prednisone—systemic scleroderma	0.000408	0.000475	CcSEcCtD
Bosentan—Urethral disorder—Methotrexate—systemic scleroderma	0.000407	0.000475	CcSEcCtD
Bosentan—Diarrhoea—Lisinopril—systemic scleroderma	0.000407	0.000474	CcSEcCtD
Bosentan—Anaemia—Prednisone—systemic scleroderma	0.0004	0.000466	CcSEcCtD
Bosentan—Angioedema—Prednisone—systemic scleroderma	0.000396	0.000461	CcSEcCtD
Bosentan—Dizziness—Lisinopril—systemic scleroderma	0.000393	0.000458	CcSEcCtD
Bosentan—Erythema multiforme—Methotrexate—systemic scleroderma	0.000393	0.000458	CcSEcCtD
Bosentan—Nausea—Mycophenolic acid—systemic scleroderma	0.000392	0.000457	CcSEcCtD
Bosentan—Vertigo—Prednisone—systemic scleroderma	0.000389	0.000453	CcSEcCtD
Bosentan—Eye disorder—Methotrexate—systemic scleroderma	0.000388	0.000453	CcSEcCtD
Bosentan—Syncope—Prednisone—systemic scleroderma	0.000388	0.000452	CcSEcCtD
Bosentan—Tinnitus—Methotrexate—systemic scleroderma	0.000388	0.000451	CcSEcCtD
Bosentan—Cardiac disorder—Methotrexate—systemic scleroderma	0.000386	0.000449	CcSEcCtD
Bosentan—EDNRA—G alpha (q) signalling events—EDN1—systemic scleroderma	0.000385	0.0122	CbGpPWpGaD
Bosentan—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000384	0.000447	CcSEcCtD
Bosentan—Loss of consciousness—Prednisone—systemic scleroderma	0.000381	0.000443	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.00038	0.0121	CbGpPWpGaD
Bosentan—Vomiting—Lisinopril—systemic scleroderma	0.000378	0.000441	CcSEcCtD
Bosentan—Angiopathy—Methotrexate—systemic scleroderma	0.000377	0.000439	CcSEcCtD
Bosentan—Immune system disorder—Methotrexate—systemic scleroderma	0.000375	0.000437	CcSEcCtD
Bosentan—Rash—Lisinopril—systemic scleroderma	0.000375	0.000437	CcSEcCtD
Bosentan—Dermatitis—Lisinopril—systemic scleroderma	0.000375	0.000437	CcSEcCtD
Bosentan—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000375	0.000436	CcSEcCtD
Bosentan—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000374	0.000436	CcSEcCtD
Bosentan—Chills—Methotrexate—systemic scleroderma	0.000373	0.000434	CcSEcCtD
Bosentan—Headache—Lisinopril—systemic scleroderma	0.000373	0.000434	CcSEcCtD
Bosentan—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000369	0.00043	CcSEcCtD
Bosentan—Arthralgia—Prednisone—systemic scleroderma	0.000369	0.000429	CcSEcCtD
Bosentan—Anxiety—Prednisone—systemic scleroderma	0.000367	0.000428	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000366	0.000426	CcSEcCtD
Bosentan—Discomfort—Prednisone—systemic scleroderma	0.000364	0.000424	CcSEcCtD
Bosentan—Mental disorder—Methotrexate—systemic scleroderma	0.000364	0.000424	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000363	0.0115	CbGpPWpGaD
Bosentan—Malnutrition—Methotrexate—systemic scleroderma	0.000362	0.000422	CcSEcCtD
Bosentan—Erythema—Methotrexate—systemic scleroderma	0.000362	0.000422	CcSEcCtD
Bosentan—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000357	0.000415	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000356	0.0113	CbGpPWpGaD
Bosentan—Nausea—Lisinopril—systemic scleroderma	0.000353	0.000412	CcSEcCtD
Bosentan—Oedema—Prednisone—systemic scleroderma	0.000353	0.000412	CcSEcCtD
Bosentan—Anaphylactic shock—Prednisone—systemic scleroderma	0.000353	0.000412	CcSEcCtD
Bosentan—Infection—Prednisone—systemic scleroderma	0.000351	0.000409	CcSEcCtD
Bosentan—Back pain—Methotrexate—systemic scleroderma	0.00035	0.000408	CcSEcCtD
Bosentan—Shock—Prednisone—systemic scleroderma	0.000348	0.000405	CcSEcCtD
Bosentan—Nervous system disorder—Prednisone—systemic scleroderma	0.000347	0.000404	CcSEcCtD
Bosentan—Tachycardia—Prednisone—systemic scleroderma	0.000345	0.000402	CcSEcCtD
Bosentan—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000345	0.000402	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000344	0.0109	CbGpPWpGaD
Bosentan—Skin disorder—Prednisone—systemic scleroderma	0.000343	0.0004	CcSEcCtD
Bosentan—Hyperhidrosis—Prednisone—systemic scleroderma	0.000342	0.000398	CcSEcCtD
Bosentan—Vision blurred—Methotrexate—systemic scleroderma	0.000341	0.000397	CcSEcCtD
Bosentan—Anorexia—Prednisone—systemic scleroderma	0.000337	0.000392	CcSEcCtD
Bosentan—Anaemia—Methotrexate—systemic scleroderma	0.000334	0.00039	CcSEcCtD
Bosentan—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000331	0.000386	CcSEcCtD
Bosentan—Rash—Mycophenolate mofetil—systemic scleroderma	0.000329	0.000383	CcSEcCtD
Bosentan—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000328	0.000383	CcSEcCtD
Bosentan—Headache—Mycophenolate mofetil—systemic scleroderma	0.000327	0.00038	CcSEcCtD
Bosentan—Vertigo—Methotrexate—systemic scleroderma	0.000325	0.000379	CcSEcCtD
Bosentan—Leukopenia—Methotrexate—systemic scleroderma	0.000324	0.000377	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000322	0.000375	CcSEcCtD
Bosentan—Insomnia—Prednisone—systemic scleroderma	0.00032	0.000372	CcSEcCtD
Bosentan—Paraesthesia—Prednisone—systemic scleroderma	0.000317	0.00037	CcSEcCtD
Bosentan—Cough—Methotrexate—systemic scleroderma	0.000316	0.000368	CcSEcCtD
Bosentan—Dyspepsia—Prednisone—systemic scleroderma	0.000311	0.000362	CcSEcCtD
Bosentan—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00031	0.000361	CcSEcCtD
Bosentan—Arthralgia—Methotrexate—systemic scleroderma	0.000308	0.000359	CcSEcCtD
Bosentan—Chest pain—Methotrexate—systemic scleroderma	0.000308	0.000359	CcSEcCtD
Bosentan—Decreased appetite—Prednisone—systemic scleroderma	0.000307	0.000358	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000306	0.000356	CcSEcCtD
Bosentan—Fatigue—Prednisone—systemic scleroderma	0.000305	0.000355	CcSEcCtD
Bosentan—Discomfort—Methotrexate—systemic scleroderma	0.000304	0.000355	CcSEcCtD
Bosentan—Constipation—Prednisone—systemic scleroderma	0.000302	0.000352	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—RHOB—systemic scleroderma	0.0003	0.00954	CbGpPWpGaD
Bosentan—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000295	0.000344	CcSEcCtD
Bosentan—Infection—Methotrexate—systemic scleroderma	0.000293	0.000342	CcSEcCtD
Bosentan—Nervous system disorder—Methotrexate—systemic scleroderma	0.00029	0.000337	CcSEcCtD
Bosentan—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000289	0.000337	CcSEcCtD
Bosentan—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000289	0.000337	CcSEcCtD
Bosentan—Skin disorder—Methotrexate—systemic scleroderma	0.000287	0.000334	CcSEcCtD
Bosentan—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000286	0.000333	CcSEcCtD
Bosentan—Anorexia—Methotrexate—systemic scleroderma	0.000282	0.000328	CcSEcCtD
Bosentan—Urticaria—Prednisone—systemic scleroderma	0.000281	0.000327	CcSEcCtD
Bosentan—Body temperature increased—Prednisone—systemic scleroderma	0.000279	0.000325	CcSEcCtD
Bosentan—Abdominal pain—Prednisone—systemic scleroderma	0.000279	0.000325	CcSEcCtD
Bosentan—Hypotension—Methotrexate—systemic scleroderma	0.000276	0.000321	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—RHOB—systemic scleroderma	0.000272	0.00866	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—EDN1—systemic scleroderma	0.000271	0.00862	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000269	0.000313	CcSEcCtD
Bosentan—Insomnia—Methotrexate—systemic scleroderma	0.000267	0.000311	CcSEcCtD
Bosentan—Paraesthesia—Methotrexate—systemic scleroderma	0.000265	0.000309	CcSEcCtD
Bosentan—Dyspnoea—Methotrexate—systemic scleroderma	0.000263	0.000307	CcSEcCtD
Bosentan—Somnolence—Methotrexate—systemic scleroderma	0.000263	0.000306	CcSEcCtD
Bosentan—Hypersensitivity—Prednisone—systemic scleroderma	0.00026	0.000303	CcSEcCtD
Bosentan—Dyspepsia—Methotrexate—systemic scleroderma	0.00026	0.000303	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.00026	0.00825	CbGpPWpGaD
Bosentan—Decreased appetite—Methotrexate—systemic scleroderma	0.000257	0.000299	CcSEcCtD
Bosentan—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000255	0.000297	CcSEcCtD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000255	0.0081	CbGpPWpGaD
Bosentan—Fatigue—Methotrexate—systemic scleroderma	0.000255	0.000297	CcSEcCtD
Bosentan—Asthenia—Prednisone—systemic scleroderma	0.000254	0.000295	CcSEcCtD
Bosentan—Pain—Methotrexate—systemic scleroderma	0.000253	0.000294	CcSEcCtD
Bosentan—Pruritus—Prednisone—systemic scleroderma	0.00025	0.000291	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000243	0.00774	CbGpPWpGaD
Bosentan—Diarrhoea—Prednisone—systemic scleroderma	0.000242	0.000282	CcSEcCtD
Bosentan—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000242	0.000281	CcSEcCtD
Bosentan—Urticaria—Methotrexate—systemic scleroderma	0.000235	0.000273	CcSEcCtD
Bosentan—Dizziness—Prednisone—systemic scleroderma	0.000234	0.000272	CcSEcCtD
Bosentan—Body temperature increased—Methotrexate—systemic scleroderma	0.000233	0.000272	CcSEcCtD
Bosentan—Abdominal pain—Methotrexate—systemic scleroderma	0.000233	0.000272	CcSEcCtD
Bosentan—Vomiting—Prednisone—systemic scleroderma	0.000225	0.000262	CcSEcCtD
Bosentan—Rash—Prednisone—systemic scleroderma	0.000223	0.00026	CcSEcCtD
Bosentan—Dermatitis—Prednisone—systemic scleroderma	0.000223	0.000259	CcSEcCtD
Bosentan—Headache—Prednisone—systemic scleroderma	0.000221	0.000258	CcSEcCtD
Bosentan—Hypersensitivity—Methotrexate—systemic scleroderma	0.000218	0.000253	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—RHOB—systemic scleroderma	0.000215	0.00683	CbGpPWpGaD
Bosentan—Asthenia—Methotrexate—systemic scleroderma	0.000212	0.000247	CcSEcCtD
Bosentan—Nausea—Prednisone—systemic scleroderma	0.00021	0.000244	CcSEcCtD
Bosentan—Pruritus—Methotrexate—systemic scleroderma	0.000209	0.000243	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—SMAD7—systemic scleroderma	0.000208	0.00661	CbGpPWpGaD
Bosentan—Diarrhoea—Methotrexate—systemic scleroderma	0.000202	0.000235	CcSEcCtD
Bosentan—Dizziness—Methotrexate—systemic scleroderma	0.000195	0.000227	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—RHOB—systemic scleroderma	0.000195	0.0062	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—EDN1—systemic scleroderma	0.000194	0.00617	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000188	0.00598	CbGpPWpGaD
Bosentan—Vomiting—Methotrexate—systemic scleroderma	0.000188	0.000219	CcSEcCtD
Bosentan—Rash—Methotrexate—systemic scleroderma	0.000186	0.000217	CcSEcCtD
Bosentan—Dermatitis—Methotrexate—systemic scleroderma	0.000186	0.000217	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—CCL2—systemic scleroderma	0.000185	0.00589	CbGpPWpGaD
Bosentan—Headache—Methotrexate—systemic scleroderma	0.000185	0.000216	CcSEcCtD
Bosentan—Nausea—Methotrexate—systemic scleroderma	0.000175	0.000204	CcSEcCtD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000174	0.00554	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RHOB—systemic scleroderma	0.000161	0.00512	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—EDN1—systemic scleroderma	0.000153	0.00487	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HSPG2—systemic scleroderma	0.000152	0.00483	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SMAD7—systemic scleroderma	0.000149	0.00473	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CSK—systemic scleroderma	0.000147	0.00466	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000142	0.00453	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—EDN1—systemic scleroderma	0.000139	0.00442	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CCL2—systemic scleroderma	0.000133	0.00422	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RHOB—systemic scleroderma	0.000115	0.00366	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—EDN1—systemic scleroderma	0.00011	0.00349	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HSPG2—systemic scleroderma	0.000109	0.00345	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CSK—systemic scleroderma	0.000105	0.00334	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EDN1—systemic scleroderma	9.95e-05	0.00317	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CCL2—systemic scleroderma	9.51e-05	0.00302	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—HSPG2—systemic scleroderma	8.37e-05	0.00266	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EDN1—systemic scleroderma	8.22e-05	0.00261	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CCL2—systemic scleroderma	6.8e-05	0.00216	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CTGF—systemic scleroderma	6.34e-05	0.00202	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.27e-05	0.002	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EDN1—systemic scleroderma	5.88e-05	0.00187	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCL2—systemic scleroderma	5.62e-05	0.00179	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NOS3—systemic scleroderma	5.01e-05	0.00159	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.76e-05	0.00151	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCL2—systemic scleroderma	4.02e-05	0.00128	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MMP9—systemic scleroderma	4.02e-05	0.00128	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOS3—systemic scleroderma	3.58e-05	0.00114	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TGFB1—systemic scleroderma	3.31e-05	0.00105	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MMP9—systemic scleroderma	2.87e-05	0.000914	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HSPG2—systemic scleroderma	2.79e-05	0.000889	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NOS3—systemic scleroderma	2.76e-05	0.000878	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TGFB1—systemic scleroderma	2.37e-05	0.000753	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CTGF—systemic scleroderma	2.12e-05	0.000673	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.84e-05	0.000586	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.4e-05	0.000444	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NOS3—systemic scleroderma	9.22e-06	0.000293	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NOS3—systemic scleroderma	6.08e-06	0.000193	CbGpPWpGaD
